24 July 2020 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature Review
Ashraf Imam1ACDEF*, Sadi A. Abukhalaf1ABCEF, Riham Imam1BCD, Samir Abu-Gazala1AEF, Hadar Merhav1ACD, Abed Khalaileh1ABCEFDOI: 10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
Table 5 Characteristics and management of the COVID-19 kidney transplant patients with death as the outcome.
| Variable (n=9) | Value |
|---|---|
| Age in years (mean) | 66.2 |
| >65y | 55.5% |
| <65y | 44.5% |
| Sex, Male | 55.5% |
| Kidney transplant years age (Mean) | 9.7 |
| Comorbidities | |
| HTN | 88.8% |
| DM | 33.3% |
| COPD | 100% |
| Laboratories | |
| Lymphopenia (<1*10/l) | 66.6% |
| High CRP (>5 mg/dl) | 66.6% |
| Acute kidney injury | 44.4% |
| Baseline Immunosuppression regimen | |
| Tac, MMF, Pred | 44.4% |
| Management | |
| Immunosuppression | |
| Held tacrolimus | 3/6 (50%) |
| Reduced tacrolimus | 2/6 (33.3%) |
| No change tacrolimus | 1/6 (16.6%) |
| Held mycophenolate mofetil | 6/6 (100%) |
| Held prednisone | 2/7 (28.5%) |
| No change prednisone | 5/7 (71.4%) |
| Held ciclosporin | 1/1 (100%) |
| Held sirolimus | 1/1 (100%) |
| Held mizoribine | 1/1 (100%) |
| Tx targets COVID-19 | |
| Lopinavir/Ritonavir | 44.4% |
| Hydroxychloroquine | 55.5% |
| Oseltamivir | 11.1% |
| Antibiotics | 55.5% |
| Intravenous methylprednisolone | 33.3% |
| Intravenous immunoglobulin | 22.2% |
| ICU admission | 33.3% |
| MV requirement | 55.5% |
| Disease days duration (median, range) | 9 (5–40) |